Post SELECT: Selenium on trial

Future Medicinal Chemistry

Volumn 5, Issue 2, 2013, Pages 163-174

  Sharma, Arun K ^a   Amin, Shantu ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; SELENIUM; TEMOZOLOMIDE;

CHEMOPROPHYLAXIS; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; FORECASTING; HUMANS; NEOPLASMS; SELENIUM;

EID: 84873290591     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.203     Document Type: Review

References (109)

1. Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur. J. Clinical Nutr. 58(3), 391-402 (2004). (Pubitemid 38443698)
2. Goldhaber SB. Trace element risk assessment: essentiality vs. toxicity. Regul. Toxicol. Pharmacol. 38(2), 232-242 (2003). (Pubitemid 37194529)
3. Spallholz JE, Boylan LM, Larsen HS. Advances in understanding selenium's role in the immune system. Ann. NY Acad. Sci. 587, 123-139 (1990). (Pubitemid 20249271)
4. Taylor EW, Nadimpalli RG, Ramanathan CS. Genomic structures of viral agents in relation to the biosynthesis of selenoproteins. Biol. Trace Elem. Res. 56(1), 63-91 (1997). (Pubitemid 27198251)
5. Hawkes WC, Hornbostel L. Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol. Psychiatry 39(2), 121-128 (1996). (Pubitemid 26045299)
6. Benton D, Cook R. The impact of selenium supplementation on mood. Biol. Psychiatry 29(11), 1092-1098 (1991).
7. Sher L. Depression and suicidal behavior in alcohol abusing adolescents: possible role of selenium deficiency. Minerva Pediatr. 60(2), 201-209 (2008). (Pubitemid 351859879)
8. Benton D. Selenium intake, mood and other aspects of psychological functioning. Nutr. Neurosci. 5(6), 363-374 (2002). (Pubitemid 35469536)
9. Mistry HD, Broughton Pipkin FB, Redman CW, Poston L. Selenium in reproductive health. Am. J. Obstet. Gynecol. 206(1), 21-30 (2012).
10. Vanderpas JB, Contempre B, Duale NL et al. Iodine and selenium deficiency associated with cretinism in northern Zaire. Am. J. Clin. Nutr. 52(6), 1087-1093 (1990). (Pubitemid 120008217)
11. Knekt P, Heliövaara M, Aho K, Alfthan G, Marniemi J, Aromaa A. Serum selenium, serum alpha-tocopherol, and the risk of rheumatoid arthritis. Epidemiology 11(4), 402-405 (2000). (Pubitemid 30428932)
12. McCloy R. Chronic pancreatitis at Manchester, UK. Focus on antioxidant therapy. Digestion 59(Suppl. 4), 36-48 (1998). (Pubitemid 28548606)
13. Flatt A, Pearce N, Thomson CD, Sears MR, Robinson MF, Beasley R. Reduced selenium in asthmatic subjects in New Zealand. Thorax 45(2), 95-99 (1990). (Pubitemid 20068002)
14. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall Jr. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol. Biomarkers Prev. 11(11), 1285-1291 (2002). (Pubitemid 35340362)
15. El-Bayoumy K. The role of selenium in cancer prevention. In: Cancer Principles and Practice of Oncology (4th). J.B. Lippincott, PA, USA, 1-15 (1991).
16. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol. Ther. 79(3), 179-192 (1998). (Pubitemid 28393874)
17. Combs GF Jr, Lu J. Selenium as a cancer preventive agent. In: Selenium: Its Molecular Biology and Role in Human Health. Hatfield DL (Ed.). Springer, NY, USA, 205-218 (2001).
18. Reinhold U, Biltz H, Bayer W, Schmidt KH. Serum selenium levels in patients with malignant melanoma. Acta. Derm. Venereol. 69(2), 132-136 (1989). (Pubitemid 19057352)
19. Mikac-Devic M, Vukelic N, Kljaic K. Serum selenium level in patients with colorectal cancer. Biol. Trace Elem. Res. 33, 87-94 (1992).
20. Milde D, Novak O, Stu ka V, Vyslou il K, Macha ek J. Serum levels of selenium, manganese, copper, and iron in colorectal cancer patients. Biol. Trace Elem. Res. 79(2), 107-114 (2001). (Pubitemid 32324543)
21. Sancak B, Ünal A, Candan S, Cokun U, Günel N. Association between oxidative stress and selenium levels in patients with breast cancer at different clinical stages. J. Trace Elem. Exp. Med. 16, 87-94 (2003). (Pubitemid 36927361)
22. McConnell KP, Jager RM, Bland KI, Blotcky AJ. The relationship of dietary selenium and breast cancer. J. Surg. Oncol. 15(1), 67-70 (1980). (Pubitemid 10021304)
23. Schrauzer GN, Molenaar T, Mead S, Kuehn K, Yamamoto H, Araki E. Selenium in the blood of Japanese and American women with and without breast cancer and fibrocystic disease. Jpn. J. Cancer Res. 76(5), 374-377 (1985). (Pubitemid 15227299)
24. Krsnjavi H, Beker D. Serum selenium level as a diagnostic parameter in breast cancer. Helv. Chir. Acta. 59(1), 231-234 (1992).
25. Lopez-Saez JB, Senra-Varela A, Pousa-Estevez L. Selenium in breast cancer. Oncology 64(3), 227-231 (2003). (Pubitemid 36438807)
26. Sundstrom H, Yrjanheikki E, Kauppila A. Serum selenium in patients with ovarian cancer during and after therapy. Carcinogenesis 5(6), 731-734 (1984). (Pubitemid 14082840)
27. Pourmand G, Salem S, Moradi K, Nikoobakht MR, Tajik P, Mehrsai A. Serum selenium level and prostate cancer: a case-control study. Nutr. Cancer 60(2), 171-176 (2008). (Pubitemid 351451274)
28. Yadav SP, Gera A, Singh I, Chanda R. Serum selenium levels in patients with head and neck cancer. J. Otolaryngol. 31(4), 216-219 (2002).
29. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc. Nutr. Soc. 64(4), 527-542 (2005). (Pubitemid 41705454)
30. Ip C. Lessons from basic research in selenium and cancer prevention. J. Nutr. 128(11), 1845-1854 (1998). (Pubitemid 28509845)
31. Zeng H, Combs GF Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J. Nutr. Biochem. 19(1), 1-7 (2008). (Pubitemid 350213396)
32. Brown KM, Arthur Jr. Selenium, selenoproteins and human health: a review. Public Health Nutr. 4(2B), 593-599 (2001). (Pubitemid 32524579)
33. Facompre N, El-Bayoumy K. Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res. 69(7), 2699-2703 (2009).
34. Sanmartin C, Plano D, Font M, Palop JA. Selenium and clinical trials: new therapeutic evidence for multiple diseases. Curr. Med. Chem. 18(30), 4635-4650 (2011).
35. Sanmartin C, Plano D, Font M, Palop JA. Kinase regulation by sulfur and selenium containing compounds. Curr. Cancer Drug Targets 11(4), 496-523 (2011).
36. Marshall Jr. Larry Clark's legacy: randomized controlled, selenium-based prostate cancer chemoprevention trials. Nutr. Cancer 40(1), 74-77 (2001). (Pubitemid 34037517)
37. Mugesh G, Du Mont WW, Sies H. Chemistry of biologically important synthetic organoselenium compounds. Chem. Rev. 101(7), 2125-2179 (2001). (Pubitemid 35381674)
38. Brigelius-Flohe R. Selenium compounds and selenoproteins in cancer. Chem. Biodivers. 5(3), 389-395 (2008).
39. Drake EN. Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med. Hypotheses 67(2), 318-322 (2006). (Pubitemid 43825626)
40. Sinha R, El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr. Cancer Drug Targets 4(1), 13-28 (2004). (Pubitemid 38332561)
41. Zhao R, Domann FE, Zhong W. Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol. Cancer Ther. 5(12), 3275-3284 (2006). (Pubitemid 46092071)
42. Novoselov SV, Calvisi DF, Labunskyy VM et al. Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 24(54), 8003-8011 (2005). (Pubitemid 41746744)
43. Sanmartin C, Plano D, Sharma AK, Palop JA. Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy. Int. J. Mol. Sci. 13, 9649-9672 (2012).
44. El-Bayoumy K. Overview: the late Larry C. Clark showed the bright side of the moon element (selenium) in a clinical cancer prevention trial. Nutr. Cancer 40(1), 4-5 (2001). (Pubitemid 34037507)
45. Sharma A, Sharma AK, Madhunapantula SV et al. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin. Cancer Res. 15(5), 1674-1685 (2009).
46. Sharma AK, Sharma A, Desai D et al. Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J. Med. Chem. 51(24), 7820-7826 (2008).
47. Sharma AK, Kline CL, Berg A, Amin S, Irby RB. The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Clin. Cancer Res. 17(13), 4474-4483 (2011).
48. Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol. Cancer Ther. 7(5), 1297-1308 (2008).
49. Cheng Y, Sk UH, Zhang Y et al. Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. PLoS ONE 7(4), e35104 (2012).
50. Clark LC, Dalkin B, Krongrad A et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br. J. Urol. 81(5), 730-734 (1998). (Pubitemid 28316638)
51. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1), 39-51 (2009).
52. Ledesma MC, Jung-Hynes B, Schmit TL, Kumar R, Mukhtar H, Ahmad N. Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol. Med .17(1-2), 134-143 (2011).
53. El-Bayoumy K, Sinha R. Molecular chemoprevention by selenium: a genomic approach. Mutat. Res. 591(1-2), 224-236 (2005). (Pubitemid 41654851)
54. Yan L, Demars LC. Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice. Int. J. Cancer 131(6), 1260-1266 (2012).
55. El-Bayoumy K, Richie JP Jr, Boyiri T et al. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. Cancer Epidemiol. Biomarkers Prev. 11(11), 1459-1465 (2002). (Pubitemid 35340385)
56. Micke O, Schomburg L, Buentzel J, Kisters K, Muecke R. Selenium in oncology: from chemistry to clinics. Molecules 14(10), 3975-3988 (2009).
57. Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG. A nutrient approach to prostate cancer prevention: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr. Cancer 62(7), 896-918 (2010).
58. El-Bayoumy K. The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr. Cancer 61(3), 285-286 (2009).
59. Costello AJ. A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology 57(4 Suppl. 1), 182-184 (2001). (Pubitemid 33733943)
60. Duffield-Lillico AJ, Dalkin BL, Reid ME et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial. BJU Int. 91(7), 608-612 (2003). (Pubitemid 36583728)
61. Novotny L, Rauko P, Kombian SB, Edafiogho IO. Selenium as a chemoprotective anti-cancer agent: reality or wishful thinking? Neoplasma 57(5), 383-391 (2010).
62. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M. Selenium for preventing cancer. Cochrane Database Syst. Rev.(5), CD005195 (2011).
63. Männistö S, Alfthan G, Virtanen M, Kataja V, Uusitupa M, Pietinen P. Toenail selenium and breast cancer-a case-control study in Finland. Eur. J.Clin. Nutr. 54(2), 98-103 (2000). (Pubitemid 30162879)
64. Brozmanova J, Manikova D, Vlckova V, Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. Arch. Toxicol. 84(12), 919-938 (2010).
65. Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O. Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr. Cancer Ther. 9(2), 136-141 (2010).
66. Ibanez E, Plano D, Font M et al. Synthesis and antiproliferative activity of novel symmetrical alkylthio-and alkylseleno-imidocarbamates. Eur. J. Med. Chem. 46(1), 265-274 (2011).
67. Moreno E, Plano D, Lamberto I et al. Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: synthesis and study of their potential cytotoxic activity in vitro. Eur. J. Med. Chem. 47(1), 283-298 (2012).
68. Plano D, Baquedano Y, Moreno-Mateos D et al. Selenocyanates and diselenides: a new class of potent antileishmanial agents. Eur. J. Med. Chem. 46(8), 3315-3323 (2011).
69. Plano D, Ibanez E, Calvo A, Palop JA, Sanmartin C. Novel library of selenocompounds as kinase modulators. Molecules 16(8), 6349-6364 (2011).
70. Roy SS, Ghosh P, Sk UH et al. Naphthalimide based novel organoselenocyanates: finding less toxic forms of selenium that would retain protective efficacy. Bioorg. Med. Chem. Lett. 20(23), 6951-6955 (2010).
71. Sharma AK, Sk UH, He P, Peters JM, Amin S. Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity. Bioorg. Med. Chem. Lett. 20(14), 4050-4052 (2010).
72. Nguyen N, Sharma A, Sharma AK et al. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev. Res. (Phila.) 4(2), 248-258 (2011).
73. Sk UH, Sharma AK, Ghosh S, Bhattacharya S. Synthesis and biological evaluation of novel spiro 6-methoxytetralin-1,3́-pyrrolidine based organoselenocyanates against cadmium-induced oxidative and hepatic damage in mice. Eur. J. Med. Chem. 45(8), 3265-3273 (2010).
74. Ip C, Ganther HE. Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis 13(7), 1167-1170 (1992).
75. Huber RE, Criddle RS. Comparison of the chemical properties of selenocysteine and selenocystine with their sulfur analogs. Arch. Biochem. Biophys. 122(1), 164-173 (1967).
76. Jacob C, Giles GI, Giles NM, Sies H. Sulfur and selenium: the role of oxidation state in protein structure and function. Angew. Chem. Int. Ed. Engl. 42(39), 4742-4758 (2003). (Pubitemid 37314599)
77. Arnér ES. Selenoproteins - what unique properties can arise with selenocysteine in place of cysteine? Exp. Cell Res. 316, 1296-1303 (2010).
78. Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 56(1), 5-51 (2001). (Pubitemid 32063165)
79. Drewnowski A, Gomez-Carneros C. Bitter taste, phytonutrients, and the consumer: a review. Am. J. Clin. Nutr. 72(6), 1424-1435 (2000).
80. Cinciripini PM, Hecht SS, Henningfield JE, Manley MW, Kramer BS. Tobacco addiction: implications for treatment and cancer prevention. J. Natl Cancer Inst. 89(24), 1852-1867 (1997). (Pubitemid 28009821)
81. Fenwick GR, Heaney RK, Mullin WJ. Glucosinolates and their breakdown products in food and food plants. Crit. Rev. Food Sci. Nutr. 18(2), 123-201 (1983).
82. Zhang Y, Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res. 54(7 Suppl.), 1976s-1981s (1994). (Pubitemid 24132159)
83. Maheo K, Morel F, Langouet S et al. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. Cancer Res. 57(17), 3649-3652 (1997). (Pubitemid 27381200)
84. Chen YR, Wang W, Kong AN, Tan TH. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J. Biol. Chem. 273(3), 1769-1775 (1998). (Pubitemid 28133709)
85. Yu R, Mandlekar S, Harvey KJ, Ucker DS, Kong AN. Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res. 58(3), 402-408 (1998). (Pubitemid 28087397)
86. Kassahun K, Davis M, Hu P, Martin B, Baillie T. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 10(11), 1228-1233 (1997). (Pubitemid 27524827)
87. Conaway CC, Getahun SM, Liebes LL et al. Disposition of glucosinolates and sulforaphane in humans after ingestion of steamed and fresh broccoli. Nutr. Cancer 38(2), 168-178 (2000). (Pubitemid 32762016)
88. Chung FL, Conaway CC, Rao CV, Reddy BS. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 21(12), 2287-2291 (2000). (Pubitemid 32049237)
89. Chung FL, Jiao D, Conaway CC, Smith TJ, Yang CS, Yu MC. Chemopreventive potential of thiol conjugates of isothiocyanates for lung cancer and a urinary biomarker of dietary isothiocyanates. J. Cell. Biochem. Suppl. 27, 76-85 (1997). (Pubitemid 28222122)
90. Beecher CW. Cancer preventive properties of varieties of Brassica oleracea: a review. Am. J. Clin. Nutr. 59(5 Suppl.), 1166S-1170S (1994). (Pubitemid 24144895)
91. Talalay P, Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J. Nutr. 131(11 Suppl.), 3027S-3033S (2001). (Pubitemid 33070774)
92. Ip C, Ganther HE. Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis 13, 1167-1170 (1992).
93. Clark LC, Combs GF Jr, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. nutritional prevention of cancer study group. JAMA 276(24), 1957-1963 (1996). (Pubitemid 26427723)
94. Combs GF Jr, Lu J. Selenium as a Cancer Preventive Agent. Kluwer Academic Publishers, Dordrecht, The Netherlands, 205-218 (2001).
95. Combs GJ Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol. Ther. 79(3), 179-192 (1998). (Pubitemid 28393874)
96. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23, 3-25 (1997). (Pubitemid 27046991)
97. Crampsie MA, Jones N, Das A et al. Phenylbutyl isoselenocyanate modulates Phase I and II enzymes and inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-induced DNA adducts in mice. Cancer Prev. Res. (Phila.) 4(11), 1884-1894 (2011).
98. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63(11), 2881-2890 (2003). (Pubitemid 36667160)
99. Stahl JM, Sharma A, Cheung M et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64(19), 7002-7010 (2004). (Pubitemid 39331010)
100. Crampsie MA, Pandey MK, Desai D, Spallholz J, Amin S, Sharma AK. Phenylalkyl isoselenocyanates vs phenylalkyl isothiocyanates: thiol reactivity and its implications. Chem. Biol. Interact. 200(1), 28-37 (2012).
101. Krishnegowda G, Prakasha Gowda AS, Tagaram HR et al. Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway. Bioorg. Med. Chem. 19(20), 6006-6014 (2011).
102. Vine KL, Locke JM, Ranson M, Benkendorff K, Pyne SG, Bremner JB. In vitro cytotoxicity evaluation of some substituted isatin derivatives. Bioorg. Med. Chem. 15(2), 931-938 (2007). (Pubitemid 44880712)
103. Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP. Melanoma prevention using topical PBISe. Cancer Prev. Res. (Phila.) 4(6), 935-948 (2011).
104. Desai D, Salli U, Vrana KE, Amin S. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 20(6), 2044-2047 (2010).
105. Karelia N, Desai D, Hengst JA, Amin S, Rudrabhatla SV, Yun J. Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells. Bioorg. Med. Chem. Lett. 20(22), 6816-6819 (2010).
106. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol. Ther. 13(9), (2012).
107. Desai D, Kaushal N, Gandhi UH et al. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem. Biol. Interact. 188(3), 446-456 (2010).
108. Desai D, Sinha I, Null K et al. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells. Int. J. Cancer 127(1), 230-238 (2010).
109. US Department of Agriculture, Agricultural Research Service National Nutrient Database for Standard Reference, Release 24. Nutrient Data Laboratory Home Page. www.ars.usda.gov/ba/bhnrc/ndl